In his petition for certiorari, Stephen Thaler had asked the U.S. Supreme Court to reverse the Federal Circuit decision in which the court ruled that artificial intelligence (AI) could not be listed as the sole inventor.  However, the Supreme Court has now denied Thaler’s petition, and it is now effectively up to Congress to act to promote any change on the issue.  As Thaler noted in his petition, this issue is unlikely to be appealed to the Supreme Court again.   Particularly, the Federal Circuit has already denied en banc rehearing; additionally, the Federal Circuit is the only court of appeals with jurisdiction over questions of patent law, so no circuit split will occur.  Indeed, as the law is essentially settled at this point, Applicants are unlikely to even file patent applications listing AI as the sole inventor, and thus the fact pattern is unlikely to repeat itself.

Continue Reading The Future of AI Inventorship Following Denial of Stephen Thaler’s Petition

PatentNext Takeaway: The U.S. Copyright Office originally granted copyright registration to a comic book titled “Zarya of the Dawn.” However, upon learning that the comic book included images created by an AI tool, the Office canceled the original registration but allowed a new registration more narrowly focused on the contributions of the human author, namely the text of the comic book and the selection of arrangements of the AI-generated images. 

Continue Reading U.S. Copyright Office Partially Allows Registration of Work having AI-generated Images (“Zarya of the Dawn”)

What is ChatGPT?

ChatGPT is an artificial intelligence (AI) model developed by OpenAI. In particular, ChatGPT is a type of “language” model designed to respond with a natural language reply when prompted with a text-based question. The “Chat” in ChatGPT refers to this question-and-answer design, where ChatGPT behaves like a ChatBot. 

Continue Reading ChatGPT and Intellectual Property (IP) related Topics

I am excited to announce the publication of the Intellectual Property Owner (IPO)’s white paper on “Software and Medical Device Guidance: A Global Perspective.”

The paper was authored by the IPO’s Software and Medical Device Subcommittee, which I had the honor and pleasure of leading in 2022. The Subcommittee reports to the IPO’s Software Committee. 

Continue Reading Announcing IPO white paper on a Global Perspective on Software and Medical Device Guidance 

PatentNext Summary: Following the August 2022 Federal Circuit decision in Thaler v. Vidal, 43 F.4th 1207 (Fed. Cir. 2022), in which the court ruled that artificial intelligence (AI) could not be an inventor by itself, the USPTO has now requested comments regarding AI and inventorship. 

Continue Reading USPTO Request for Comments on AI as an Inventor

PatentNext Summary: Software and computer-implemented inventions (CII) have experienced explosive growth in recent years. This article looks at laws of jurisdictions in Southeast Asia, comparing the status of enforcement and protection of software and CII in various Southeast Asia countries.

Continue Reading Patenting Software And Computer-Implemented Inventions In Southeast Asia  

PatentNext Summary: The life sciences and healthcare fields produce big data, which Artificial Intelligence (AI) tools can use to train AI models to assist doctors, patients, researchers, and other stakeholders in various ways. In the intellectual property (IP) space, there has been explosive growth in this area, with AI-based patent filings addressing trending areas, including disease identification and diagnosis, drug discovery, personalized medicine, and clinical trials, among others. These trends are expected to continue though challenges remain, such as the balance between the need for health-related data to train AI models and privacy and ethical concerns in using such data.

Continue Reading The Intersection of Artificial Intelligence (AI), Life Sciences, Healthcare, and Intellectual Property (IP)

PatentNext Summary: Artificial Intelligence (AI) typically involves certain common aspects such as training data and AI models trained from that training data. Nonetheless, a recent Patent Trial and Appeal Board (PTAB) decision found that it is not always obvious to combine these common aspects to render an AI-based medical device invention unpatentable.

Continue Reading PTAB finds Artificial Intelligence (AI) Medical Device Patent not so Obvious

PatentNext Summary: Artificial Intelligence (AI) systems are expected to increasingly provide automated decisions impacting, for example, home ownership, job recruitment, and other important life events. In this way, such AI systems have the power to impact a wide variety of people and should be trained in a manner that eliminates bias and promotes fairness. The White House has recently published a Blueprint for an AI Bill of Rights that seeks to acknowledge and address these potentially inherent ethical risks of AI systems. 

Continue Reading Ethical Considerations of Artificial Intelligence (AI) and the White House’s Blueprint for an AI Bill of Rights

PatentNext Summary: Virtual Reality (VR)-related patents are expected to rise with the onset of the Metaverse. Given that VR is fundamentally a software technology, how do courts review VR-related patents? Early cases show that courts will apply similar scrutiny as for other software-related technologies, where VR-related patents will need to satisfy current patent eligibility standards, e.g., by showing an “improvement” to underlying computing technology.  

Continue Reading Patenting Virtual Reality (VR) Inventions in the Age of the Metaverse